What parameters now qualify a patient infected with HCV for shortened first-line therapy?
With the approvals of SOF/VEL/VOX and GLE/PIB, what is the new management approach for DAA-experienced patients with HCV infection?
Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs.
Which patients, who have achieved a sustained virologic response with HCV treatment, need to be screened for hepatocellular carcinoma? Here’s my approach.
Following recent updates to the AASLD HBV guidelines, what criteria determine optimal therapy for immune-active CHB?
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.